Boosting return on investment for a new class of drug


Around the average human body are more than one trillion microbes, some of which produce biomolecules implicated in chronic diseases. Our client developed a variety of methods for reducing the negative effects of one such biomolecule, including a new class of drugs to inhibit its production. Because these new drugs target microbes, and not human cells, they have potential applications beyond human health. Our client asked Innovia to explore these applications to help create multiple revenue streams for this new class of drug.


Innovia investigated the synthesis routes and locations of the target biomolecule across a broad range of activities and industries in order to map the possible application areas. We assessed the relevance of each application by examining the sources of precursors, the conditions required for synthesis, and the existing pathways for metabolism or degradation. Using both a first-principles analysis and a detailed literature review, we examined the reasons why production of the biomolecule could have negative consequences in each application area. By bringing together our technical understanding and our commercial knowledge, we were able to identify the applications that would be most beneficial for the prospective customer.


Three of the applications identified were commercially significant: in industrial biotechnology, human cosmetics, and animal health. For each, we identified the best routes to commercialisation, and potential industrial partners for development and regulatory approval. Ultimately, we highlighted several new avenues for commercial development and recommended a clear strategy to achieve a strong return on R&D investment.